Biomarker: F314-IgE Soybean

Overview

Soybean (Glycine max) is a legume and a recognized food allergen. Soy proteins can trigger IgE-mediated reactions after ingestion, including urticaria, gastrointestinal symptoms, respiratory symptoms, or anaphylaxis, although reactions are often mild. Exposure most commonly occurs through soybeans, soy flour, soy protein, tofu, tempeh, soy beverages, and other foods containing soy ingredients. Serum-specific IgE testing can help evaluate sensitization to soybean, but results require interpretation alongside the clinical history and, when appropriate, other allergy testing.

Clinical Use Cases

Evaluation of suspected IgE-mediated soy allergy: Measures soybean-specific IgE in patients with symptoms temporally associated with soy exposure.
Investigation of exposure-related symptoms: Supports evaluation of immediate skin, gastrointestinal, respiratory, or systemic symptoms occurring after soy ingestion.
Serum-specific IgE assessment: Provides a blood-based measure of IgE antibodies directed against soybean proteins.
Integration with clinical history: Helps an allergist assess whether sensitization is consistent with the patient’s reported exposure, symptom pattern, timing, and reproducibility.
Assessment of cross-reactive sensitization: Soybean component testing may help distinguish primary sensitization to soy storage proteins from birch-pollen-related sensitization involving Gly m 4.
Clarification of uncertain diagnoses: Results may be considered with skin-prick testing and, when clinically indicated, a medically supervised oral food challenge. A positive specific-IgE result alone does not establish clinical allergy.

Specimen Types

Serum: Commonly used for measurement of soybean-specific IgE and, where available, IgE to individual soybean components.
Venous blood: The source specimen from which serum or plasma is prepared for laboratory IgE testing.

Measurement Methods

Allergen-specific IgE testing: In-vitro immunoassays measure IgE antibodies directed against soybean extract in serum or blood. The result indicates sensitization and must be interpreted with clinical findings.
Component-resolved diagnostics: Measures IgE to individual soybean proteins, including Gly m 4, Gly m 5, Gly m 6, and Gly m 8, when clinically available. These results may help characterize sensitization patterns and distinguish primary soy sensitization from pollen-related cross-reactivity.
Skin-prick testing: May be used as part of the broader allergy evaluation, but it does not replace clinical assessment or establish allergy independently.
Oral food challenge: A supervised exposure procedure may be used when the diagnosis remains uncertain and is considered the most accurate method for confirming or excluding food allergy.

Test Preparation and Influencing Factors

Fasting: Fasting is generally not required for serum-specific IgE collection unless other tests obtained at the same time require it.
Medications: Most medications do not prevent blood-specific IgE measurement. Medication review remains important because some drugs can affect skin-prick testing or management of an allergic reaction.
Clinical history: The food form, amount consumed, timing of symptoms, reproducibility, and co-factors such as exercise are important for interpretation.
Sensitization versus allergy: Detectable soybean-specific IgE indicates immunologic sensitization, not necessarily symptomatic food allergy.
Total IgE concentration: Very high total IgE may complicate interpretation of some specific-IgE results; the quantitative result should not be interpreted independently of the clinical context.
Age: Soy sensitization and clinical reactivity can change over time, particularly during childhood. Age-specific clinical interpretation may therefore be relevant.
Cross-reactive sensitization: Birch-pollen sensitization may produce IgE binding to the soybean component Gly m 4, which can complicate interpretation of extract-based soybean testing.
Extract composition: A negative soybean-extract result may not exclude sensitization to a particular component, especially when the clinically relevant protein is underrepresented or unstable in the extract.
Component pattern: Sensitization to Gly m 5 or Gly m 6 has been associated in human studies with more clinically significant primary soy allergy, but component results do not independently predict an individual reaction.

Cross-Reactivity

Birch pollen: Gly m 4 is a soybean PR-10 protein homologous to the major birch-pollen allergen Bet v 1. IgE cross-reactivity between these proteins can cause soybean sensitization or symptoms in some birch-pollen-allergic individuals.
PR-10 protein family: Gly m 4 belongs to the pathogenesis-related protein 10 family. This structurally related protein family is also involved in pollen-food allergy syndrome.
Primary soybean allergens: Gly m 5, a 7S globulin, and Gly m 6, an 11S globulin, are soybean storage proteins associated with primary soy sensitization. Their recognition pattern differs from the birch-pollen-related Gly m 4 pattern.
Clinical relevance: Immunologic cross-reactivity does not always produce symptoms. Some individuals with IgE recognizing both Bet v 1 and Gly m 4 may tolerate soy, while others may develop oral or systemic reactions.
Interpretation of testing: Soybean component testing may help identify whether a positive soybean result is more consistent with primary sensitization or birch-pollen-related cross-reactivity, but clinical history remains essential.

Synonyms

Common name: Soybean
Scientific name:Glycine max
Food allergen name: Soy
Allergen designation: F14 soybean in some allergen-testing nomenclature systems
Named soybean components: Gly m 4, Gly m 5, Gly m 6, and Gly m 8